Listen

Goals

  • To improve the recognition of hereditary cancer. For this we need to extend our knowledge of the phenotype of cancer predisposition syndromes and novel genetic factors.  To achieve this, both phenotypic and genetic DNA information from blood and tumors is essential. 
  • To improve the diagnostics of hereditary cancer and meet patient needs. For this we need to evaluate and optimize strategies to give patients access to genetic testing and the optimal genetic diagnostic test strategies.  
  • To improve the treatment of hereditary cancer. For this we need to evaluate the effect of current treatment strategies that mostly follow the guidelines of a given tumor type. As for our rare patient groups, more tailored treatment strategies are necessary and warrant exploration. The increasing knowledge on the mechanisms underlying the most frequent cancer predisposition syndromes provides ample opportunities to achieve this goal.  
  • To improve cancer prevention in individuals with a genetic predisposition to develop cancer. For this we need to optimize access to current multidisciplinary surveillance programs, risk reducing interventions (e.g., surgery or medication), and novel preventive measures such as vaccination, and to evaluate the efficiency of these measures. 


go to main content
Research Research programs Hereditary cancer:

Our mission

We aim to improve aspects of the entire care pathway, from recognition to diagnosis and treatment as well as the prevention of hereditary cancer.

Goals

See some of the most important goals for this research program.

read more

Research groups contributing to this research program

Cancer genomics

Richarda de Voer's research group focuses on the genetic predispositions and mutational processes that underly cancer development, especially in the context of development at an early age in Iife and concerning the development of multiple primary tumors throughout the life of a single individual.

Cancer microbiology

Annemarie Boleij's research group explores the gut microbiome's role in cancer development, focusing on high-risk colorectal cancer, bacterial biofilms, and host-microbe interactions in colorectal, gastrointestinal, and breast cancers.

Gastrointestinal pathology

Iris Nagtegaal's research group is an interdisciplinary research group, with backgrounds in pathology, translational biomarker research, hereditary cancer, microbiology, machine learning and bioinformatics. 

Spokesperson

dr. Richarda de Voer

contact form

Spokesperson

prof. dr. Marjolijn Ligtenberg

contact form

Spokesperson

dr. Chella van der Post

contact form